相关实验视频

Updated: May 22, 2025

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

Published on: April 22, 2022

用含有迷香提取物的食补充剂逆转糖分

Zoe Draelos¹, Vivian Bucay², Jacqueline Watchmaker³

¹Dr. Draelos is with Dermatology Consulting Services, PLLC in High Point, North Carolina.

The Journal of clinical and aesthetic dermatology

|March 13, 2025

概括

迷香提取物含有丰富的迷香酸,通过防止先进的糖化最终产品 (AGEs) 来对抗皮肤衰老有前途. 这种食补充剂通过其抗糖和抗氧化特性支持皮肤健康.

科学领域:

皮肤病学和化学
自然产品化学自然产品化学
生物化学生物化学

背景情况:

糖化应激和活性氧物种通过形成先进的糖化最终产品 (AGEs) 加快皮肤衰老.
这些AGE有助于原蛋白和弹性质的降解,损害皮肤结构和功能.
越来越多地探索饮食干预措施,以减轻皮肤衰老过程的潜力.

研究的目的:

为了研究迷香提取物食补充剂的皮肤脱糖潜力.
评估迷香提取物在支持皮肤健康和逆转衰老迹象方面的有效性.
探索迷香酸在迷香的抗糖作用中的作用.

主要方法:

对相关的英语语言研究进行了全面的PubMed文献搜索.
该审查侧重于临床和临床前研究,研究迷香提取物对糖化和皮肤衰老的影响.
分析了主要活性化合物,如罗斯马林酸及其机制.

主要成果:

迷香提取物及其活性化合物迷香酸 (RA) 显示出显著的抗糖和抗氧化特性.
这些化合物有效地抑制了AGE的形成,并降低了蛋白质碳化.
迷香提取物在保护原蛋白和弹性质,逆转糖化方面显示出潜力,通过口服或局部应用有利于皮肤健康.

结论:

迷香提取物和RA表现出有希望的抗糖作用,中断了AGE的形成和交叉链接.
这些发现表明迷香提取物是针对衰老的护肤配方的潜在成分.
需要进一步的研究,以充分阐明迷香提取物在皮肤健康中的机制和治疗应用.

关键词:

糖性压力是因为糖性压力.先进的糖化最终产品 (AGEs)它具有抗糖作用的效果.具有抗氧化特性具有抗氧化特性营养保健品营养保健品迷香提取物迷香提取物罗斯马林酸是一种酸.皮肤老化皮肤老化皮肤健康皮肤健康

更多相关视频

Preparation of Naringenin Solution for In Vivo Application

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

Production and Detection of Reactive Oxygen Species ROS in Cancers

Production and Detection of Reactive Oxygen Species ROS in Cancers

Published on: November 21, 2011

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...